FMX 8
Alternative Names: FMX-8Latest Information Update: 13 May 2017
Price :
$50 *
At a glance
- Originator FerruMax Pharmaceuticals
- Class Antianaemics; Recombinant fusion proteins
- Mechanism of Action Hepcidin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 12 May 2017 Discontinued - Phase-II for Anaemia in USA (IV), because no recent reports on development were identified further to phase II trial termination
- 17 Jul 2014 FerruMax Pharmaceuticals plans a phase 0 trial in Anaemia in USA (NCT02228655)
- 25 Mar 2014 FerruMax Pharmaceuticals terminates a phase IIa trial in Anaemia in USA (NCT01873534)